Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more ...

Aurinia Pharmaceuticals announced a complete overhaul of its C-suite on Monday, sparking both the biotech stock and hopes of an acquisition.

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its remaining stake at a loss, Quotient Therapeutics enters a multi-year research ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.

Dr. Danielle Kelvas, MD, founder of DKMD Consulting, today, shared a timely perspective on the evolution of pharmaceutical marketing, tracing its transformation from physician-centered communication ...

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

MXene nanosheet-based catalytic membranes efficiently degrade antibiotics in pharmaceutical wastewater while reducing ...

New stablecoin strategy fuels investor optimism.

The HDMA seeks India’s intervention as West Asian crises spike drug raw material costs by 300%. Rising prices and shortages threaten MSME viability and the supply of essential medicines nationwide.

Shares of Fennec Pharmaceuticals fell after the company reported a widened loss in the fourth quarter. Shares were trading down 11% at $6.60 on Nasdaq and were down 12% to C$8.92 ($6.50) on the ...